Clinical trial · Interventional
Standard of Care Therapy With Involved Field Radiation Therapy for Selective Recurrent Ovarian Cancer
A Phase II Trial of Standard of Care Therapy With Involved Field Radiation Therapy for Selective Recurrent Ovarian Cancer
NCT03618706CI-TRIAL-00034180unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to investigate the effect of involved-field radiotherapy for recurrent ovarian cancer after primary standard treatment. We will investigate whether the addition of involved-field RT improves 2-year PFS in those patients than that of historical data (only with other standard salvage treatments as systemic chemotherapy ± maximum tumor resection).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Recurrent Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Involved-field radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- involved-field RT + standard salvage treatment
- description
- Patients receiving involved-field RT on recurred lesions + standard salvage treatment for recurrent ovarian cancer
- interventionNames
- Radiation: Involved-field radiotherapy
Primary outcomes (1)
- measure
- 2-year progression-free survival (PFS)
- timeFrame
- 2 years after radiotherapy
Secondary outcomes (4)
- measure
- Local control of recurred lesions
- timeFrame
- 2 years after radiotherapy
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: * Pathologically confirmed ovarian carcinoma * Patients who received "standard treatment" for each stage as a primary treatment * No. of recurrent lesions: If, all in lung, or intra-abdominal or pelvis organs - ≤ 5 If, any in liver, bone, or spinal cord - ≤ 2 * Size of recurrent lesions ≤5 cm * All recurrent lesions are available for involved-field radiotherapy * Within 60 days before enrollment: * Absolute neutrophil count ANC ≥ 500 / mm3 * Platelet ≥ 50,000 / mm3 * Hb ≥ 8.0 g / dl * Good performance status (ECOG 0-1) Exclusion Criteria: * Brain metastasis * Diffuse peritoneal carcinomatosis * Malignant pleural effusion * History of previous salvage radiotherapy for recurrent lesions * History of other malignancy or severe/unstable medical condition
References
Publications (0)
Data not yet available
No reference posted for this study.